Structure Therapeutics (NASDAQ:GPCR) Trading Down 5.4% - Here's Why

Key Points

• Structure Therapeutics shares fell 5.4% to about $36.85 in mid-day trading, with volume roughly 65% below its average.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $110.91, despite some sell ratings.
• The company recently missed quarterly earnings expectations, reporting an adjusted loss of $0.49 per share versus the $0.39 loss analysts anticipated. Its lead candidate is an oral GLP-1 drug targeting obesity and type 2 diabetes.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s stock price traded down 5.4% during mid-day trading on Wednesday . The company traded as low as $36.82 and last traded at $36.8530. 313,859 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 896,918 shares. The stock had previously closed at $38.95.

Wall Street Analyst Weigh In

Several research firms have weighed in on GPCR. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen raised Structure Therapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 17th. Citizens Jmp reissued a "market outperform" rating and issued a $110.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Structure Therapeutics in a research report on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $110.91.

Structure Therapeutics Stock Performance

The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -36.89 and a beta of -1.45. The stock's 50-day simple moving average is $48.94 and its two-hundred day simple moving average is $48.03.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC increased its holdings in shares of Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company's stock worth $71,114,000 after purchasing an additional 313,600 shares during the period. Handelsbanken Fonder AB bought a new stake in shares of Structure Therapeutics in the second quarter valued at about $1,041,000. SEB Asset Management AB acquired a new stake in Structure Therapeutics during the first quarter worth about $11,811,000. Principal Financial Group Inc. increased its stake in Structure Therapeutics by 36.6% during the first quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company's stock valued at $84,531,000 after acquiring an additional 469,554 shares during the period. Finally, B Group Inc. bought a new position in Structure Therapeutics during the fourth quarter valued at about $6,260,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.